PMGC Holdings Inc. - SIC # 6726 - UNIT INVESTMENT TRUSTS, FACE-AMOUNT CERTIFICATE OFFICES, AND CLOS

Ticker Exchange SIC # Website Latest Ticker
ELAB Nasdaq 6726 pmgcholdings.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for PMGC Holdings Inc.

PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies - Jun 18th, 2025 7:52 am
Northstrive announces initiation of Phase II of AI Development Program - Jun 18th, 2025 7:20 am
Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases - Jun 17th, 2025 7:04 am
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001:2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for over 35 years - Jun 16th, 2025 6:00 am
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Electronics Manufacturing Company - Jun 9th, 2025 6:00 am
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia - May 22nd, 2025 6:16 am
PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q - May 14th, 2025 2:30 pm
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) - May 14th, 2025 6:00 am
Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22 - May 13th, 2025 6:00 am
RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health - Apr 29th, 2025 10:15 am
Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health - Apr 29th, 2025 6:00 am
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial - Apr 28th, 2025 6:00 am
Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment - Apr 24th, 2025 6:00 am
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company - Apr 16th, 2025 6:00 am
Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases - Apr 10th, 2025 6:00 am
PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K - Mar 28th, 2025 6:00 am
NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market - Mar 27th, 2025 6:00 am
Univest Securities, LLC Announces Closing of $1.48 Million Registered Direct Offering for its Client PMGC Holdings Inc. (NASDAQ: ELAB) - Mar 24th, 2025 3:00 pm
PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules - Mar 21st, 2025 12:41 pm
PMGC Holdings Announces Share Repurchases from Existing Shareholders - Mar 21st, 2025 6:00 am